Listar por autor "Bocanegra Gondán, Ana Isabel"
Mostrando ítems 1-20 de 20
-
Circulating low density neutrophils are associated with resistance to anti-PD1 immunotherapy in squamous head and neck cancer
Arrazubi, Virginia; Goñi Irigoyen, Saioa
; González Borja, Iranzu; Hernández García, Irene; Arasanz Esteban, Hugo; Pérez Sanz, Jairo; Bocanegra Gondán, Ana Isabel; Kochan, Grazyna; Escors Murugarren, David; Ruiz de Azúa, Yerani; Elizalde, Jesús María; Viúdez, Antonio; Vera García, Ruth (Wiley, 2023)
Artículo / Artikulua
Background: Identification of predictive biomarkers to Immune checkpoint inhibitors (ICIs) in head and neck cancer (HNSCC) is an unmet need. Methods: This was a prospective observational study including 25 patients with ... -
Clinical landscape of LAG-3-targeted therapy
Chocarro, Luisa ; Blanco, Ester; Arasanz Esteban, Hugo; Fernández Rubio, Leticia; Bocanegra Gondán, Ana Isabel; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Fernández Hinojal, Gonzalo; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (Elsevier, 2022)
Artículo / Artikulua 
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation ... -
Cutting-edge CAR engineering: beyond T cells
Chocarro, Luisa ; Blanco, Ester; Fernández Rubio, Leticia; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Piñeiro Hermida, Sergio; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2022)
Artículo / Artikulua
Chimeric antigen receptor (CAR)-T adoptive cell therapy is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in haematological malignancies. However, it still lacks ... -
Cutting-edge: preclinical and clinical development of the first approved LAG-3 inhibitor
Chocarro, Luisa ; Bocanegra Gondán, Ana Isabel; Blanco, Ester; Fernández Rubio, Leticia; Arasanz Esteban, Hugo; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Piñeiro Hermida, Sergio; Vera García, Ruth; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2022)
Artículo / Artikulua
Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (LAG-3) is one of the most important ... -
Early detection of hyperprogressive disease in non-small cell lung cancer by monitoring of systemic T cell dynamics
Arasanz Esteban, Hugo; Zuazo Ibarra, Miren ; Bocanegra Gondán, Ana Isabel; Gato Cañas, María; Martínez Aguillo, Maite; Morilla Ruiz, Idoia (MDPI, 2020)
Artículo / Artikulua
Hyperprogressive disease (HPD) is an adverse outcome of immunotherapy consisting of an acceleration of tumor growth associated with prompt clinical deterioration. The definitions based on radiological evaluation present ... -
La enseñanza de la inmunología en Secundaria en un contexto de pandemia
(2021) Trabajo Fin de Máster/Master Amaierako LanaLa pandemia de COVID-19 ha evidenciado la importancia de la formación científica en el área de la inmunología para la formación de ciudadanos con espíritu crítico y con capacidad de actuar y de tomar decisiones responsables ... -
Immune profiling uncovers memory T-cell responses with a Th17 signature in cancer patients with previous SARS-CoV-2 infection followed by mRNA vaccination
Echaide Górriz, Míriam; Labiano, Ibone; Delgado, Marina; Fernández de Lascoiti, Ángela; Ochoa, Patricia; Garnica, Maider; Ramos, Pablo; Chocarro, Luisa ; Fernández Rubio, Leticia; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Blanco, Ester; Piñeiro Hermida, Sergio; Morente Sancho, Pilar; Vera García, Ruth; Alsina, María; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2022)
Artículo / Artikulua
It is unclear whether patients with cancer present inherently impaired responses to COVID-19 and vaccination due to their treatments, neoplastic diseases or both. To address this question, immune profiling was performed ... -
Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors
Blanco, Ester; Chocarro, Luisa ; Fernández Rubio, Leticia; Bocanegra Gondán, Ana Isabel; Arasanz Esteban, Hugo; Echaide Górriz, Míriam; Garnica, Maider; Piñeiro Hermida, Sergio; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2023)
Artículo / Artikulua
Immunotherapies based on immune checkpoint blockade have shown remarkable clinical outcomes and durable responses in patients with many tumor types. Nevertheless, these therapies lack efficacy in most cancer patients, even ... -
Mrna vaccines against sars-cov-2: advantages and caveats
Echaide Górriz, Míriam; Chocarro, Luisa ; Bocanegra Gondán, Ana Isabel; Blanco, Ester; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2023)
Artículo / Artikulua
The application of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 infection has constituted a determinant resource to control the COVID-19 pandemic. Since the beginning of 2021, millions of doses have been administered ... -
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
Edwards, Carolyn J.; Sette, Angelica; Cox, Carl; Di Fiore, Barabara; Wyre, Chris; Sydoruk, Daniela; Yadin, David; Hayes, Philip; Stelter, Szymon; Bartlett, Phillip D.; Zuazo Ibarra, Miren ; García-Granda, María Jesús; Benedetti, Giovanni; Fiaska, Stratonik; Birkett, Neil R.; Teng, Yumin; Enever, Carrie; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Fernández, Gonzalo; Vera García, Ruth; Archer, Bethan; Osuch, Isabelle; Lewandowska, Martyna; Surani, Yasmin M.; Kochan, Grazyna; Escors Murugarren, David; Legg, James; Pierce, Andrew J. (Springer Nature, 2021)
Artículo / Artikulua
Background: improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppression restrain the capacity of T cells to provide anti-tumour activity ... -
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies
Blanco, Ester; Silva-Pilipich, Noelia; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Procopio, Antonio; Ausín, Karina; Fernández Irigoyen, Joaquín ; Fernández Rubio, Leticia; Razquin, Nerea; Igea, Ana; Garnica, Maider; Echaide Górriz, Míriam; Arasanz Esteban, Hugo; Vera García, Ruth; Escors Murugarren, David; Smerdou, Cristian; Kochan, Grazyna (Springer Nature, 2024)
Artículo / Artikulua
Background: Previous studies have shown that functional systemic immunity is required for the efficacy of PD-1/PD-L1 blockade immunotherapies in cancer. Hence, systemic reprogramming of immunosuppressive dysfunctional ... -
PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer
Bocanegra Gondán, Ana Isabel; Fernandez Hinojal, Gonzalo; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Garcia-Granda, María Jesús; Hernandez, Carlos; Ibáñez-Vea, María ; Hernandez-Marin, Berta; Martinez-Aguillo, Maite; Lecumberri, María José; Fernández de Lascoiti, Ángela; Teijeira, Lucía; Morilla, Idoia; Vera García, Ruth; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2019)
Artículo / Artikulua
PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade anticancer therapies, particularly for lung cancer. However, the reliability of this marker is still under debate. Moreover, ... -
PD-L1 in systemic immunity: unraveling its contribution to PD-1/PD-L1 blockade immunotherapy
Bocanegra Gondán, Ana Isabel; Blanco, Ester; Fernández Hinojal, Gonzalo; Chocarro, Luisa ; Zuazo Ibarra, Miren (MDPI, 2020)
Artículo / Artikulua
The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients ... -
Profound reprogramming towards stemness in pancreatic cancer cells as adaptation to AKT inhibition
Arasanz Esteban, Hugo; Hernández, Carlos; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Zuazo Ibarra, Miren (MDPI, 2020)
Artículo / Artikulua
Cancer cells acquire resistance to cytotoxic therapies targeting major survival pathways by adapting their metabolism. The AKT pathway is a major regulator of human pancreatic adenocarcinoma progression and a key pharmacological ... -
A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets
Blanco, Ester; Ibáñez-Vea, María ; Hernández, Carlos; Drici, Lylia; Martínez de Morentin Iribarren, Xabier; Gato Cañas, María; Ausín, Karina; Bocanegra Gondán, Ana Isabel; Zuazo Ibarra, Miren ; Chocarro, Luisa ; Arasanz Esteban, Hugo; Fernández Hinojal, Gonzalo; Fernández Irigoyen, Joaquín ; Smerdou, Cristian; Garnica, Maider; Echaide Górriz, Míriam; Fernández Rubio, Leticia; Morente Sancho, Pilar; Ramos-Castellanos, Pablo; Llopiz, Diana; Santamaría, Enrique; Larsen, Martin R.; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2021)
Artículo / Artikulua
Monocytic and granulocytic myeloid-derived suppressor cells together with tumor-infiltrating macrophages constitute the main tumor-infiltrating immunosuppressive myeloid populations. Due to the phenotypic resemblance to ... -
The regulators of peroxisomal acyl-carnitine shuttle CROT and CRAT promote metastasis in melanoma
Lasheras Otero, Irene; Feliu, Iker; Maíllo Ruiz de Infante, Alberto; Moreno, Haritz; Redondo Muñoz, Marta; Aldaz Donamaría, Paula; Bocanegra Gondán, Ana Isabel; Olías Arjona, Ana; Lecanda, Fernando; Fernández Irigoyen, Joaquín ; Santamaría, Enrique; Larráyoz, Ignacio M.; Gómez Cabrero, David; Wellbrock, Claudia; Vicent, Silvestre; Arozarena Martinicorena, Imanol (Elsevier, 2023)
Artículo / Artikulua
Circulating tumor cells are the key link between a primary tumor and distant metastases, but once in the bloodstream, loss of adhesion induces cell death. To identify the mechanisms relevant for melanoma circulating tumor ... -
Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies
Hernández, Carlos; Arasanz Esteban, Hugo; Chocarro, Luisa ; Bocanegra Gondán, Ana Isabel; Zuazo Ibarra, Miren (MDPI, 2020)
Artículo / Artikulua
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use ... -
Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
Escors Murugarren, David; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Blanco, Ester; Piñeiro Hermida, Sergio; Garnica, Maider; Fernández Rubio, Leticia; Vera García, Ruth; Arasanz Esteban, Hugo; Kochan, Grazyna (MDPI, 2022)
Artículo / Artikulua
PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic ... -
Systemic CD4 immunity: a powerful clinical biomarker for PD-L1/PD-1 immunotherapy
Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Vera García, Ruth (EMBO Press, 2020)
Artículo / Artikulua
The search for non-invasive systemic biomarkers of response to PD-L1/PD-1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful ... -
Understanding LAG-3 Signaling
Chocarro, Luisa ; Blanco, Ester; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Fernández Rubio, Leticia; Morente Sancho, Pilar; Fernández Hinojal, Gonzalo; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2021)
Artículo / Artikulua
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ...
